BioGaia: BioGaia’s probiotic shown to promote growth and prevent recurrent diarrhoea

Results from a randomized, controlled pilot study in 76 infants with
acute diarrhoea show that rapid diagnostic testing and Lactobacillus
reuteri Protectis supplementation for 60 days was associated with a
significant increase in 60-day adjusted standardized height and
significantly less recurrent diarrhoea compared to standard care and
placebo treatment. The study was conducted in Botswana and the
preliminary results were presented at the Infectious Disease Week in San
Diego, USA, on October 10 2015.

STOCKHOLM, Sweden–(BUSINESS WIRE)–Regulatory News:

Results from a randomized, controlled pilot study in 76 infants with
acute diarrhoea show that rapid diagnostic testing and Lactobacillus
reuteri Protectis supplementation for 60 days was associated with a
significant increase in 60-day adjusted standardized height and
significantly less recurrent diarrhoea compared to standard care and
placebo treatment. The study was conducted in Botswana and the
preliminary results were presented at the Infectious Disease Week in San
Diego, USA, on October 10 2015.

“These results are very exciting. Our trial has shown that the
administration of L. reuteri DSM 17938 shows real promise to mitigate
the devastating effects of diarrhoeal disease in sub-Saharan Africa.
Previous probiotic trials have focused on outcomes such as duration of
diarrhoea, which are somewhat relevant for families and clinicians, but
not nearly as important as a hard outcome such as standardized height,
which has been directly linked to stunting, cognitive deficiencies, and
eventual adult accomplishment”, says Associate Professor Jeffrey Pernica
at McMaster Children’s Hospital in Hamilton, Canada, who conducted the
study.

Diarrhoea kills and disables children Diarrhoea is the second leading
cause of mortality in the world among children under the age of five, as
well as a major cause of both growth failure and delayed cognitive
development. There is a clear need for improvements in diarrhoeal
disease management in resource-limited settings.

The pilot study demonstrated that the use of rapid enteric diagnostics
(permitting timely targeted antimicrobial therapy) and L. reuteri
Protectis were both feasible in a resource-limited sub-Saharan African
context. These interventions led to significant increases in growth and
decreases in recurrent diarrhoea. The next step will be to validate
these findings in a trial with a much larger number of children.

“In Botswana, as well as other sub-Saharan countries, long periods of
diarrhoea not only causes death but also leads to stunting and cognitive
impairments. The results from this pilot study are therefore very
encouraging as they indicate that our L. reuteri Protectis could
contribute, both in the short as well as in the long perspective, to a
better quality of life in these exposed children”, says Peter
Rothschild, President, BioGaia.

The preliminary results of the study were presented at the Infectious
Disease Week. (https://idsa.confex.com/idsa/2015/webprogram/Paper52622.html)
Study facts are found here (http://www.biogaia.com/sites/biogaia.com/files/Study_facts_Pernica_2015.pdf).

Latest press releases from BioGaia 2015-09-07 BioGaia to invest further
in Infant Bacterial Therapeutics AB 2015-08-18 BioGaia AB Interim Report
1 January-30 June 2015 2015-07-30 BioGaia’s oral health probiotic
reduces Candida in the elderly

BioGaia (STO:BIOGB) has published this information in accordance with
the Swedish Securities Market Act. The information was issued for
publication on 12 October 2015, 12:00 pm CET.

BioGaia is a healthcare company that develops, markets and sells
probiotic products with documented health benefits. The products are
primarily based on the lactic acid bacterium Lactobacillus reuteri,
which has probiotic, health-enhancing effects. The class B share of the
Parent Company BioGaia AB is quoted on the Mid Cap list of the NASDAQ
OMX Nordic Exchange Stockholm. www.biogaia.com

This information was brought to you by Cision http://news.cision.com

Contacts

For additional information please contact
Peter Rothschild, Chief
Executive Officer,
BioGaia: 46 8 555 293 00